The work will commence at a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center's Mission Bay campus.

The partners said they aim to demonstrate that having scientists, clinicians, and patients closer to a manufacturing site may expedite the development of breakthrough treatments.

UCSF's initial focus will be on treatments for glioblastoma, multiple myeloma, and other cancers, using updated approaches to CAR-T and CRISPR technologies. Therapies for other difficult-to-treat conditions will follow.

The San Francisco facility is part of Thermo Fisher's global pharma services network of more than 15 locations supporting cell and gene therapies.

In the facility, Thermo Fisher offers process and analytical development capabilities and clinical and commercial manufacturing services for advanced therapies derived from a patient's cells or a donor source.

Thermo Fisher also offers drug development capabilities, including discovery, clinical research, and commercialization.

"Cell therapies represent a rapidly emerging field of biotechnology with tremendous promise for future therapeutic applications," Michel Lagarde, executive vice president and chief operating officer of Thermo Fisher, said in a statement. "With a record number of cell therapy approvals granted in the last two years, and CAR-T therapies becoming earlier treatment options, we're in a golden age of biology, where new technologies and partnerships are evolving and transforming clinical care."

A*STAR partners with startup to create diabetes cell therapies tailored to Asian patients
BetaLife has acquired the rights to human induced pluripotent stem cell (iPSC) technology from Singapore’s Agency for Science, Technology, and Research...

Results of largest cell therapy trial shed light of effect on heart inflammation and strength
Physician-scientists at the Texas Heart Institute have published the results of a late-phase heart failure cell therapy clinical trial in the Journal...

Challenges and remedies for manufacturing cell therapies at scale
Cell therapies have the potential to cure human diseases rather than just treat the symptoms, and they are potentially life-changing if they can be administered...

Demand for viral vectors seen outpacing capacity growth despite investment surge
The growth in demand for viral vectors is outpacing a push to add capacity, leading to predictions that the current supply shortage will continue despite...

Thermo Fisher, Structura Biotechnology unveil particle analysis software
Thermo Fisher Scientific and Structura Biotechnology are partnering together on a new, single particle analysis software. The software will be a version...